Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SAM domain, SH3 domain, and nuclear localization signals 1 (SAMSN1)
- Target
- SAMSN1
- Molecular classification
- Adaptor protein, Scaffold protein, SAM (sterile alpha motif) domain containing protein, SH3 (Src homology 3) domain containing protein, Other (not a receptor, enzyme, channel, or transporter)
01
Overview
SAM domain, SH3 domain, and nuclear localization signals 1 (SAMSN1) is a widely conserved adaptor/scaffold protein containing SH3 and SAM domains that participates in regulatory signaling within immune cells, particularly as a negative regulator of B-cell activation. It down-regulates cellular proliferation, promotes RAC1-dependent actin cytoskeletal remodeling, and modulates activities of protein kinases such as LYN, as well as HDAC1. Disease association includes congenital glycosylation disorders and cancer, with its biological role focusing on the fine-tuning of immune cell responses.
- Other names
- HACS1NASH1SASH2SH3D6BSLy2SAM domain-containing protein SAMSN-1Hematopoietic adaptor containing SH3 and SAM domains 1SAM domain, SH3 domain, and nuclear localization signals protein 1SH3-SAM adaptor proteinNuclear localization signals, SAM and SH3 domain containing 1Src homology domain 3 (SH3)-containing adapter protein SH3 lymphocyte protein 2
02
Mechanism of action
Not applicable (no direct drugs); theoretical mechanisms would involve inhibition or activation of its scaffold/adaptor function in immune cells
03
Biological functions
Negative regulator of B-cell activationDown-regulation of cell proliferationModulation of immune cell activationPromotion of RAC1-dependent membrane ruffle formation and actin cytoskeleton reorganizationRegulation of cell spreading and polarizationStimulation of HDAC1 activityRegulation of LYN kinase activity via tyrosine phosphorylation modulation
04
Disease associations
Cancer (expression associated with various malignancies, role in immune cell function impacts tumor microenvironment)Congenital disorder of glycosylation, type IpPotential involvement in immune-related diseases
05
Safety considerations
None documented as direct therapeutic target; theoretical concerns relate to immune suppression or dysregulation if modulated
06
Interacting drugs
None specifically identified in curated sources; may be perturbed by small molecules in gene expression datasets
07
Biomarkers
Expression levels may serve as a biomarker for immune cell activation statusMay be considered for cancer studies involving immune cell infiltrate and B-cell activation
Beyond the preview
Go deeper on SAM domain, SH3 domain, and nuclear localization signals 1 (SAMSN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAM domain, SH3 domain, and nuclear localization signals 1 (SAMSN1).